TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB19190

Activity

Antibacterial Anticancer Antiviral Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

Peptipedia dbAMP 3.0 DRAMP DRAVP 2.0 HemoPI Hemolytic2 PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 9-aa standard natural multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide sequence curated from Peptipedia, dbAMP 3.0, DRAMP, and other sources, with an available 3D structural model.

Sequence

FLGFLHHLF

FASTA

>TPDB19190|Antibacterial;Anticancer;Antiviral;Hemolysis;Toxicity|length=9
FLGFLHHLF

Formula C59H79N13O10

Absent Amino Acids ARNDCEQIKMPSTWYV

Common Amino Acids LF

Mass 1130.36

PI 8.00

Basic Residues 2

Acidic Residues 0

Hydrophobic Residues 6

Net Charge +0

Boman Index -3.14

Hydrophobicity 1.444

Aliphatic Index 130.00

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

0

A

0

R

0

N

0

D

0

C

0

E

0

Q

1

G

2

H

0

I

3

L

0

K

0

M

3

F

0

P

0

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 2 I: 0 L: 3 K: 0 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0

Length

9

Formula

C59H79N13O10

Mass

1130.36

PI

8.00

Net Charge

+0

Boman Index

-3.14

Hydrophobicity

1.444

Evidence 1 Activity

Activity

Detail Source Activity Antibacterial

Source & Reference

Database Source DRAMP

Other

Evidence Text

inhibit hepatitis C virus (HCV) infection (EC50 1.08 ug/ml).

Evidence 2 Activity

Activity

Detail Source Activity Antiviral

Source & Reference

Database Source dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label	Source Definition
Antiviral	dbAMP 3.0 classified under the Anti-viral function class.

Evidence Text

inhibit hepatitis C virus (HCV) infection (EC50 1.08 ug/ml).

Evidence 3 Activity

Activity

Activity Endpoint HC50

Detail Source Activity Hemolysis

Activity Measurement 203.3 µg/mL

Hemolysis Raw

[Ref.23415044] HC50 = 203.3 µg/ml against human red blood cells.

Target

RBC Target human red blood cells

Source & Reference

Database Source Hemolytik PD_Hemolysis

Source DRAMP4

Reference

Biomaterials. 2013 Apr 34(13):3511-22.

Other

Source Activity Label	Source Definition
Hemolysis	Hemolytik experimentally validated hemolytic peptide annotation.

Evidence 4 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 203.3 µg/mL

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | 203.3 | µg/mL | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. | Biomaterials | 2013

Evidence 5 Activity

Activity

Activity Endpoint HC50

Detail Source Activity Toxicity

Activity Measurement 203.3 µg/mL

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

Hemolytic_activity: [Ref.23415044] HC50 = 203.3 µg/ml against human red blood cells. | Cytotoxicity: [Ref.23415044] CC50>500 µg/ml against Huh7.5.1 cells

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Biomaterials. 2013 Apr 34(13):3511-22.

Evidence 6 Hemolysis

Activity

Activity Measurement 203.3 µg/mL

Activity Endpoint HC50

Hemolysis Raw

[Ref.23415044] HC50 = 203.3 µg/ml against human red blood cells.

Detail Source Activity Hemolysis

Target

RBC Target human red blood cells

Source & Reference

source HemoPI PD_Hemolysis

Reference

Biomaterials. 2013 Apr 34(13):3511-22.

Source DRAMP4

Database Source PD_Hemolysis